Latest & greatest articles for clindamycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clindamycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clindamycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clindamycin

1. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial.

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. BACKGROUND: Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth. METHODS: PREMEVA (...) was a double-blind randomised controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin

Lancet2018

2. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial

Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial 29790266 2018 06 26 1471-0528 2018 May 22 BJOG : an international journal of obstetrics and gynaecology BJOG Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial. 10.1111/1471-0528.15290 To determine whether oral clindamycin reduces the risk of preterm birth (PTB) in women with abnormal vaginal microflora as evidenced by a vaginal (...) pH ≥5.0. Randomised double-blind placebo-controlled trial. Rural southern India. Pregnant women with a singleton fetus between 13 +0/7 weeks and 20 +6/7 weeks. Pregnant women were recruited during prenatal visits in Karnataka, India, from October 2013 to July 2015. Women were required to have a singleton fetus between 13 +0/7 weeks and 20 +6/7 weeks and an elevated vaginal pH (≥5.0) by colorimetric assessment. Participants were randomised to either oral clindamycin 300 mg twice daily for 5 days

EvidenceUpdates2018

3. Clindamycin

Clindamycin Top results for clindamycin - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for clindamycin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

4. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.

Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. 25785967 2015 03 19 2015 03 27 2016 12 15 1533-4406 372 12 2015 Mar 19 The New England journal of medicine N. Engl. J. Med. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. 1093-103 10.1056/NEJMoa1403789 Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired (...) methicillin-resistant Staphylococcus aureus (MRSA) is unclear. We enrolled outpatients with uncomplicated skin infections who had cellulitis, abscesses larger than 5 cm in diameter (smaller for younger children), or both. Patients were enrolled at four study sites. All abscesses underwent incision and drainage. Patients were randomly assigned in a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days. Patients and investigators were unaware of the treatment assignments and microbiologic test

NEJM2015 Full Text: Link to full Text with Trip Pro

6. Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket

Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket UTCAT2622, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket Clinical Question For dry socket prevention is it more efficacious to administer (...) clindamycin pre-surgery compared to post-surgery? Clinical Bottom Line Clindamycin is effective in preventing dry socket occurrence following tooth extraction, but there is no significant difference in preoperative versus postoperative administration. This is supported by a retrospective study in which postoperative clindamycin administration significantly decreased the incidence of dry socket. A randomized clinical trial (RCT) demonstrated clindamycin was equally efficacious, and showed no statistical

UTHSCSA Dental School CAT Library2014

7. There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics

There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics UTCAT2447, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics Clinical Question (...) In a patient undergoing a third molar extraction, will a clindamycin prophylaxis prevent postoperative inflammatory complications compared to no postoperative antibiotics? Clinical Bottom Line There is no difference in the rates of third molar post-operative inflammatory complications between patients with clindamycin, and patients without antibiotics. For immunocompetent patients undergoing third molar extractions, there is no apparent reason to provide any clindamycin antibiotic intervention

UTHSCSA Dental School CAT Library2013

8. Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery

Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery 22265220 2012 01 23 2012 03 13 2014 11 20 1879-1190 214 2 2012 Feb Journal of the American College of Surgeons J. Am. Coll. Surg. Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery. 202-7 10.1016/j.jamcollsurg.2011.10.014 Colorectal surgery may lead to infections because despite meticulous aseptic measures (...) , extravasation of microorganisms from the colon lumen is unavoidable. A prospective, randomized study was performed between January 2010 and December 2010. Patient inclusion criteria were a diagnosis of colorectal neoplasms and plans to undergo an elective curative operation. Patients were divided into 2 groups: Group 1 (intra-abdominal irrigation with normal saline) and Group 2 (intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin). The occurrence of wound infections

EvidenceUpdates2012

9. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections

Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections 21339275 2011 03 02 2011 05 10 2016 12 15 1098-4275 127 3 2011 Mar Pediatrics Pediatrics Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. e573-80 10.1542/peds.2010-2053 To compare clindamycin and cephalexin for treatment of uncomplicated skin and soft tissue infections (SSTIs) caused predominantly by community-associated (CA (...) ) methicillin-resistant Staphylococcus aureus (MRSA). We hypothesized that clindamycin would be superior to cephalexin (an antibiotic without MRSA activity) for treatment of these infections. Patients aged 6 months to 18 years with uncomplicated SSTIs not requiring hospitalization were enrolled September 2006 through May 2009. Eligible patients were randomly assigned to 7 days of cephalexin or clindamycin; primary and secondary outcomes were clinical improvement at 48 to 72 hours and resolution at 7 days. Cultures were obtained and tested

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

10. Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis

Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis | Therapeutics Initiative Independent Healthcare Evidence > > Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Introduction Pharmaceutical Services Division (PSD) requested a systematic review of Clindesse for the treatment of non-pregnant women ≥ 18 years of age (...) with bacterial vaginosis. Drug Clindesse is a semi-solid white cream containing 2% clindamycin phosphate, which is a water-soluble ester of the semi-synthetic antibiotic produced by a 7 (S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycea. The recommended dose is a single intravaginal administration on one day. Disease Bacterial vaginosis is a common vaginal infection caused by an imbalance in the vaginal flora. In bacterial vaginosis there is suppression of lactobacilli

Therapeutics Letter2010

11. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne

Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne Seidler EM, Kimball AB (...) CRD summary The authors concluded that at two to four weeks, combination benzoyl peroxide plus salicylic acid had the best profile for treating acne vulgaris; at 10 to 12 weeks, this combination treatment was similar to benzoyl peroxide/clindamycin treatment. Potential limitations with the review process and the uncertain quality of included trials suggest that the authors’ conclusions should be treated with caution. Authors' objectives To compare the efficacy of benzoyl peroxide, clindamycin

DARE.2010

12. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin]

[Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM. Klindamycin til gravide med asymptomatisk bakteriell vaginose. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 11 - 2010. 2010 Authors' conclusions Clindamycin treatment of pregnant women

Health Technology Assessment (HTA) Database.2010

13. Veltin (clindamycin phosphate and tretinoin) Gel

Veltin (clindamycin phosphate and tretinoin) Gel Drug Approval Package: Veltin (clindamycin phosphate and tretinoin) NDA #050803 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Veltin (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025% Company: Stiefel, a GSK company Application No.: 050803 Approval Date: 07/16/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

14. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients

An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients 18805603 2009 01 02 2009 01 30 2014 11 20 1097-6787 59 5 2008 Nov Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris (...) : assessment of efficacy and safety in 2813 patients. 792-800 10.1016/j.jaad.2008.06.040 We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were randomized to receive clindamycin-BPO 2.5%, individual active ingredients, or vehicle in two identical, double-blind, controlled 12-week, 4-arm studies evaluating

EvidenceUpdates2008

15. Clindamycin 1% and benzoyl peroxide 5% gel (Duac once daily gel)

Clindamycin 1% and benzoyl peroxide 5% gel (Duac once daily gel) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Clindamycin 1% and benzoyl peroxide 5% gel (Duac Ò Once Daily Gel) No. 92/04 Stiefel Laboratories Summary of Recommendation 13 April, 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

Scottish Medicines Consortium2004

16. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.

Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. 12660054 2003 03 27 2003 04 08 2015 06 16 0140-6736 361 9362 2003 Mar 22 Lancet (London, England) Lancet Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. 983-8 Abnormal vaginal flora (...) vaginal flora or bacterial vaginosis, in accordance with Nugent's criteria. We randomly allocated 494 women with one of these signs to receive either clindamycin 300 mg or placebo orally twice daily for 5 days. Primary endpoints were spontaneous preterm delivery (birth > or =24 but <37 weeks) and late miscarriage (pregnancy loss > or =13 but <24 weeks). Analysis was intention to treat. Nine women were lost to follow-up or had elective termination. Thus, we analysed 485 women with complete outcome data

Lancet2003

17. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion

Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Martinez M J, Freire A, Castro I, Inaraja M T, Ortega A, Del Campo V, Rodriguez I, Bardan B, Morano L E, Garcia J F Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology examined in the study was a pharmacist-intervention (through an information sheet) for the promotion of sequential therapy with antibiotics (clindamycin), defined as the early change from

NHS Economic Evaluation Database.2000

18. Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Fabian T C, Boucher B A, Croce M C Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Aztreonam-clindamycin (A-C) versus gentamicin-clindamycin (G-C) in the treatment of penetrating abdominal injury. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult patients with suspected penetrating intraabdominal injury

NHS Economic Evaluation Database.1996

19. Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest.

Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. 8813984 1996 10 31 1996 10 31 2015 06 16 0140-6736 348 9030 1996 Sep 21 Lancet (London, England) Lancet Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. 781-3 In the treatment of patients with inflamed ischaemic ulcers in peripheral arterial occlusive disease, high tissue concentrations (...) of antibiotics (TCA) are important. With local transvenous pressure injection in Biers' arterial arrest (TVA-Bier) higher TCAs are assumed to be obtained but they have not been measured. Two groups of 16 patients each with ischaemic foot ulcers were studied. In one group, patients received a mean of 284 (SD 116) mg gentamicin and in the other, 1200 mg clindamycin. The antibiotics were given intravenously, intra-arterially, and by TVA-Bier in a randomised order at intervals of 48 hours. Biopsy samples were

Lancet1996

20. Meta-analysis of parenteral clindamycin dosing regimens

Meta-analysis of parenteral clindamycin dosing regimens Meta-analysis of parenteral clindamycin dosing regimens Meta-analysis of parenteral clindamycin dosing regimens Rovers J P, Ilersich A L, Einarson T R Authors' objectives To evaluate the differences in clinical outcomes for 2 different dosages of parenteral clindamycin, 600 and 900 mg, both 8 hourly, in adult patients with intra-abdominal infection or female pelvic infection. Searching MEDLINE, EMBASE and International Pharmaceutical (...) Abstracts were searched for English language articles describing clindamycin use in humans. Additional sources were personal and drug information centre files, and the reference lists of retrieved papers. Study selection Study designs of evaluations included in the review Comparative studies of both open and blind design were included. Specific interventions included in the review Parenteral dosages of clindamycin, 600 mg or 900 mg 8 hourly. Comparable treatments included any other regimen

DARE.1995